References
- Uhlenhake EE. Optimal treatment of actinic keratoses. Clin Interv Aging. 2013;8:29–35.
- Peris K, Micantonio T, Piccolo D, et al. Dermatoskopische merkmale der aktinischen keratose. JDDG-J Ger Soc Dermatol. 2007;5:970–976.
- Stockfleth E. The importance of treating the field in actinic keratosis. J Eur Acad Dermatol Venereol. 2017;31:8–11.
- Ulrich M, Krueger-Corcoran D, Roewert-Huber J, et al. Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses. Dermatology. 2010;220:15–24.
- Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42:1–2.
- Altmeyer PD med. P. KIN D48.9 [Internet]; 2017 [cited 2017 Feb 12]. Available from https://www.enzyklopaedie-dermatologie.de/dermatologie/kin-14501#authors
- Schmitz L, Gambichler T, Gupta G, et al. Actinic keratoses show variable histological basal growth patterns – a proposed classification adjustment. J Eur Acad Dermatol Venereol. 2018;32:745–751.
- Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther (Heidelb). 2015;5:19–35.
- Rosen T, Lebwohl MG, Zografos P. Prevalence and awareness of actinic keratosis: barriers and opportunities. J Am Acad Dermatol. 2013;68:S2.
- Memon AA, Tomenson JA, Bothwell J, et al. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol. 2000;142:1154–1159.
- Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol. [Internet]. 2000;115:273–277. DOI:10.1046/j.1523-1747.2000.00048.x
- Flohil SC, Van Der Leest RJT, Dowlatshahi EA, et al. Prevalence of actinic keratosis and its risk factors in the general population: the rotterdam study. J Invest Dermatol.[Internet]. 2013;133:1971–1978. DOI:10.1038/jid.2013.134
- Traianou A, Ulrich M, Apalla Z, et al. Risk factors for actinic keratosis in eight European centres: a case-control study. Br J Dermatol. 2012;167:36–42.
- Stockfleth E, Ulrich C, Meyer T, et al. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res. 2002;160:251–258.
- Esmann S. Patients’ Perspectives on Actinic Keratosis. Curr Probl Dermatol. 2014 [cited 2014 Dec 7];18:8–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25561200
- Perera E, McGuigan S, Sinclair R. Cost for the treatment of actinic keratosis on the rise in Australia. F1000Res. 2014;3:1–11.
- Kirby JS, Gregory T, Liu G, et al. Variation in the cost of managing actinic keratosis. JAMA Dermatol. 2017;153:265–269.
- Cohen JL. Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol. 2010;3:39–44.
- Dirschka T, Gupta G, Micali G, et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J Dermatolog Treat. 2017;28:431–442.
- Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157:34–40.
- Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004;43:687–692.
- Actikerall summary of product characteristics. Pharmaceut Med. 2014; [cited 2020 Feb 18]. Available from: https://www.medicines.org.uk/emc/medicine/24614.
- Stockfleth E, Kerl H, Zwingers T, et al. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011;165:1101–1108.
- Szeimies RM, Dirschka T, Prechtl A, et al. Wirksamkeit von niedrig-dosiertem 5-fluorouracil/salizylsäure in abhängigkeit von der behandlungsdauer bei aktinischen keratosen. JDDG-J Ger Soc Dermatol. 2015;13:430–438.
- Gaspari AA. Mechanism of action and other potential roles of an immune response modifier. Cutis. 2007;79:36–45.
- Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43:1–2.
- Schön M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst. 2003;95:1138–1149.
- Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007;157:133–141.
- Jorizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007;57:265–268.
- Micali G, Lacarrubba F, Nasca MR, et al. Topical pharmacotherapy for skin cancer: part II. clinical applications. J Am Acad Dermatol. 2014;70:979.e1–979.e12.
- Alchin DR. Ingenol Mebutate: a succinct review of a succinct therapy. Dermatol Ther (Heidelb). 2014;4:157–164.
- Zarchi K, Jemec GBE. Ingenol mebutate: from common weed to cancer cure. Curr Probl Dermatol. 2015;46:136–142.
- Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010–1019.
- EMA suspends Picato as a precaution while review of skin cancer risk continues [Internet]. [cited 2020 Feb 12]; 3–5. Available from: https://www.ema.europa.eu/en/news/ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues
- Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62:582–590.
- Werner RN, Stockfleth E, Connolly SM, et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis - international league of dermatological societies in cooperation with the European Dermatology Forum - short version. J Eur Acad Dermatol Venereol. 2015;29:2069–2079.
- Hanke CW, Swanson N, Bruce S, et al. Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. J Drugs Dermatol. 2011;10:165–170.
- Gupta G, Stockfleth E, Peris K, et al. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis. . J Eur Acad Dermatol Venereol. 2015;29:1840–1842.
- Tambone S, Fargnoli MC, Capizzi R, et al. Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series. G Ital di Dermatologia e Venereol. 2018;153:333–337.
- Witheiler DD, Lawrence N, Cox SE, et al. Long-term efficacy and safety of Jessner’s solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatologic Surg. 1997;23:191–196.
- Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis. 2002;70:30–36.
- Pomerantz H, Hogan D, Eilers D, et al. Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol. 2015;151:952–960.
- Loven K, Stein L, Furst K, et al. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24:990–1000.
- Stockfleth E, Ferrandiz C, Grob JJ, et al. Development of a treatment algorithm for actinic keratoses: a European consensus. Eur J Dermatol. 2008;18:651–659.
- Smith S, Piacquadio D, Morhenn V, et al. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol. 2003;2:629–635.
- Efudix 5% cream summary of product characteristics [Internet]; [cited 2019 Dec 30]; 1–6. Available from: https://www.medicines.org.uk/emc/product/9260/smpc
- Diclofenac sodium 3%. summary of product characteristics. [Internet]; [cited 2019 Dec 30]; 1–3. Available from: https://www.medicines.org.uk/emc/product/6385/smpc
- Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol. 2003;44:40–43.
- John E, Wolf MD Jr., Joseph Richard Taylor MD. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002;146:94–100.
- Wolf E, Utech M, Stehle P, et al. Oral high-dose vitamin D dissolved in oil raised serum 25-hydroxy-vitamin D to physiological levels in obese patients after sleeve gastrectomy — a double-blind, randomized, and placebo-controlled trial. Obes Surg. 2004;1821–1829. DOI:10.1007/s11695-015-2004-0
- Nelson C. Diclofenac gel in the treatment of actinic keratoses. Ther Clin Risk Manag. 2011;7:207–211.
- Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol. 2003;48:227–232.
- Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix®) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat. 2003;14:99–106.
- Pariser D, Loss R, Jarratt M, et al. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2008;59:569–576.
- Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 2004;140:41–46.
- Hauschild A, Stockfleth E, Popp G, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol. 2009;160:1066–1074.
- Dirschka T, Radny P, Dominicus R, et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol. 2013;168:825–836.
- Marmur ES, Schmults CD, Goldberg DJ. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatologic Surg. 2004;30:264–271.
- Reinhold U. A review of BF-200 ALA for the photodynamic treatment of mild-to-moderate actinic keratosis. Futur Oncol. 2017;13:2413–2428.
- Lacour JP, Ulrich C, Gilaberte Y, et al. Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol. 2015;29:2342–2348.
- Rubel DM, Spelman L, Murrell DF, et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol. 2014;171:1164–1171.
- Mordon S, Vignion-Dewalle AS, Thecua E, et al. Can daylight-PDT be performed indoor? G Ital di Dermatologia e Venereol. 2018;153:811–816.
- Stockfleth E. The paradigm shift in treating actinic keratosis: a comprehensive strategy. J Drugs Dermatol. 2012;11:1462–1470.
- Actinic keratosis treatment market overview, share analysis and industry forecast to 2024 [Internet]. MRFR/Pharma/1746-CR; 2019 [cited 2019 Dec 24]; 1–25. Available from: https://www.marketresearchfuture.com/reports/actinic-keratosis-treatment-market-2366
- Röwert-Huber J, Patel MJ, Forschner T, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156:8–12.
- Marketresearchfuture. Actinic keratosis treatment market research report - global forecast till 2024; 2019.
- Drug summary sinecatechins. Citeline-Inf Pharm Intell. 2017.
- Drug summary nanoparticle paclitaxel, nanology. Citeline-Inf Pharm Intell. 2019.
- Drug summary kx2-391. Citeline-Inf Pharm Intell. 2019;01.
- Nami B, Wang Z. Genetics and expression profile of the Tubulin gene superfamily in breast cancer subtypes and its relation to taxane resistance. Cancers (Basel). 2018;10;274.
- TUBB tubulin beta class I [Homo sapiens (human)] - Gene - NCBI [Internet]; 2016 [cited 2019 Dec 27]. Available from: http://www.ncbi.nlm.nih.gov/gene/203068
- NanOlogy touts preclinical data for inhaled NanoPac cancer drug [Internet]; 2018 [cited 2019 Dec 31]; 1–6. Available from: https://www.drugdeliverybusiness.com/nanology-touts-preclinical-study-of-inhaled-nanopac-cancer-drug/
- DFB soria gives update on enrollment in phase 2 clinical trial of SOR007 (Nanoparticle Paclitaxel) ointment for actinic keratosis opus biotech communications or [Internet]; 2017 [cited 2019 Dec 31]; 1–2. Available from: https://www.businesswire.com/news/home/20170926005145/en/DFB-Soria-Update-Enrollment-Phase-2-Clinical
- Study of SOR007 ointment for actinic keratosis [Internet]; 2017 [cited 2019 Dec 31]; 1–9. Available from: https://clinicaltrials.gov/ct2/show/NCT03083470
- DFB soria completes a phase 2 clinical trial of submicron particle paclitaxel anhydrous ointment for actinic keratosis [Internet]; 2019 [cited 2019 Dec 31]. Available from: http://nanology.us/wp-content/uploads/2018/09/SORIA_AK_Phase_2_trial_comple_9_18_.pdf
- Safety and Efficacy study of AM001 cream in the treatment of actinic keratosis [Internet]; 2019 [cited 2019 Dec 31]; 1–6. Available from: https://clinicaltrials.gov/ct2/show/NCT03210740
- Study comparing AM001 cream to vehicle in the treatment of plaque psoriasis - full text view - ClinicalTrials.gov.pdf [Internet]; [cited 2019 Dec 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT01938599
- A multi-center study to evaluate the efficacy and safety of KX2-391 ointment 1% on AK on face or scalp [Internet]; 2017 [cited 2019 Dec 31]; 1–7. Available from: https://clinicaltrials.gov/show/NCT03285477
- A Ph2a, Open-Label, Multicenter, Activity & Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp [Internet]; 2019 [cited 2019 Dec 31]; 2–7. Available from https://clinicaltrials.gov/show/NCT02838628
- Press releases athenex announces phase ii clinical study results for KX2-391 ointment for the treatment of actinic keratosis in the american academy of dermatology meeting [Internet]; 2018 [cited 2019 Dec 31]; 1–7. Available from: http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-newsArticle&ID=2333323
- Press Releases Athenex, Inc. Announces first patient recruitment in phase III clinical trials for KX-01 ointment for actinic keratosis [Internet]; 2017 [cited 2019 Dec 31]; 10–13. Available from: http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-newsArticle&ID=2302542
- Athenex announces that two phase 3 pivotal efficacy studies of KX2-391 in actinic keratosis achieved their primary endpoints | athenex, inc.pdf [Internet]; [cited 2019 Dec 31]. Available from: https://ir.athenex.com/news-releases/news-release-details/athenex-announces-two-phase-3-pivotal-efficacy-studies-kx2-391?ID=2360203&c=254495&p=irol-newsArticle
- Good prospects for athenex/almirall following PhIII actinic keratosis results [Internet]; 2018 [cited 2019 Dec 31]; 1–2. Available from: https://scrip.pharmaintelligence.informa.com/SC123494/Good-Prospects-For-AthenexAlmirall-Following-PhIII-Actinic-Keratosis-Results
- Drug summary furosemide + digoxin. Citeline-Inf Pharm Intell. 2019.
- First-in-human study of CLS003 ICVT in subjects with cutaneous warts [Internet]; 2014 [cited 2019 Dec 31]; 10–14. Available from: https://clinicaltrials.gov/ct2/show/NCT02106260
- Topical ionic contra-viral therapy in actinic keratosis - full text view - ClinicalTrials.gov.pdf [Internet]; [cited 2019 Dec 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT03684772
- Drug summary VDA-1102. Citeline-Inf Pharm Intell. 2019.
- VDA-1102 IV [Internet]; [cited 2019 Dec 31]; 10–13. Available from: http://www.vidacpharma.com/pipeline/vda-1102-iv
- VDA-1102 ointment [Internet]; [cited 2019 Dec 31]; 17–20. Available from: http://www.vidacpharma.com/pipeline/vda-1102-ointment
- Corporate fact sheet [Internet]; 2018 [cited 2019 Dec 31]. Available from: http://www.vidacpharma.com/images/Vidac_Pharma_one-pager_July_2018.pdf
- Session PO. IM02. 05 - immune response to therapies 2 [Internet]; 2018 [cited 2019 Dec 31]; 8083. Available from: https://www.abstractsonline.com/pp8/#!/4562/presentation/8083
- VDA-1102 clinical trials [Internet]; [cited 2019 Dec 31]; 10–13. Available from: http://www.vidacpharma.com/clinical-trials/vda-1102-ointment-clinical-trials
- Efficacy and safety of VDA-1102 ointment in the treatment of actinic keratosis [Internet]; 2017 [cited 2019 Dec 31]; 1–8. Available from: https://clinicaltrials.gov/show/NCT02844777
- News & events vidac pharma completes $ 9 million series A financing I advances phase 2 studies with VDA-1102 in actinic keratosis [Internet]; [cited 2019 Dec 31]; 10–13. Available from: http://www.vidacpharma.com/news/66-vidac-pharma-completes-9-million-series
- Vidac pharma reports positive results from phase 2a proof-of-concept trial of VDA-1102 ointment in actinic keratosis [Internet]; 2017 [cited 2019 Dec 31]. Available from: https://www.businesswire.com/news/home/20171012005313/en/Vidac-Pharma-Report
- Study to evaluate the efficacy, safety, and tolerability of topical VDA-1102 ointment in subjects with actinic keratosis (Phase2b) [Internet]; 2018 [cited 2019 Dec 31]; 1–8. Available from: https://clinicaltrials.gov/ct2/show/NCT03538951
- News & events vidac pharma announces initiation of phase 2B clinical trial of VDA-1102 ointment in patients with [Internet]; 2018 [cited 2019 Dec 31]. Available from: http://www.vidacpharma.com/news-events/news/85-vidac-pharma-announces-initiation-of-phase-2b-clinical-trial-of-vda-1102-ointment-in-patients-with-actinic-keratosis